Balyasny Asset Management
CRBP icon

Balyasny Asset Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Balyasny Asset Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-65,201
Closed -$612K – 3076
2026
Q1 		$612K Sell
65,201
-68,110
-51% -$573K ﹤0.01% 2272
2025
Q4 		$1.09M Buy
133,311
+109,893
+469% +$1.36M ﹤0.01% 2154
2025
Q3 		$296K Buy
+23,418
New +$223K ﹤0.01% 2583
2024
Q4 		– Sell
-39,516
Closed -$815K – 2823
2024
Q3 		$815K Buy
+39,516
New +$2.02M ﹤0.01% 2045

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management's CRBP Position: Q2 2026 in Review

Balyasny Asset Management sold out of Corbus Pharmaceuticals (CRBP) in Q2 2026, closing a stake of 65,201 shares — an estimated $612K sold.

Balyasny Asset Management first reported a position in CRBP in Q3 2024 and held it in 4 quarters. The position peaked at $1.09M in Q4 2025. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Balyasny Asset Management reported no remaining Corbus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 65,201 Corbus Pharmaceuticals shares in Q2 2026, an estimated $612K.
  • Balyasny Asset Management first reported a position in Corbus Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Balyasny Asset Management's Corbus Pharmaceuticals position peaked at $1.09M in Q4 2025.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.